Technology evaluation: Sch-58500, Canji
Barnard, D.L.
Current Opinion in Molecular Therapeutics 2(5): 586-592
2000
ISSN/ISBN: 1464-8431 PMID: 11249761 Document Number: 524237
Sch-58500 is a gene therapy utilizing the p53 gene and is under development by Canji and Schering-Plough for the potential treatment of various types of cancer. It is in phase II/III clinical trials in the US for stage III ovarian cancer [328228,328893], phase II clinical trials for hepatocellular and colorectal cancer metastatic to the liver [273331,324279], and phase I clinical trials for several other types of cancer [282801,284932,328228].